-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 17, Sichuan Kelun submitted an application for the 4 types of imitations of nintedanib ethanesulfonate soft capsules.
The first domestic imitation of this product was taken by CSPC in March this year; on December 20, Hunan Kelun Submitted the application for the imitation of Cefmetazole Sodium/Sodium Chloride Injection for 3 types of listing.
At present, only Suzhou Otsuka Pharmaceutical has obtained approval for this product.
.
.
The latest two products of Kelun are expected to win the domestic market.
Second
.
The first domestic imitation of this product was taken by CSPC in March this year; on December 20, Hunan Kelun Submitted the application for the imitation of Cefmetazole Sodium/Sodium Chloride Injection for 3 types of listing.
At present, only Suzhou Otsuka Pharmaceutical has obtained approval for this product.
.
.
The latest two products of Kelun are expected to win the domestic market.
Second
.
Figure 1: The situation of Kelun's recently reported products
Source: CDE official website
Figure 2: Sales of nintedanib (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
It is reported that nintedanib is a small molecule tyrosine kinase inhibitor, the original research company is Boehringer Ingelheim, and its global sales in 2020 will exceed 2 billion euros (approximately US$2.
25 billion)
.
The original research drug was approved to enter the domestic market in 2017 for the treatment of systemic sclerosis-related interstitial lung disease and for the treatment of idiopathic pulmonary fibrosis
.
According to data from Mi Nei.
com, in the first half of 2021 , the sales of this product in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have exceeded 20 million yuan, with an average increase in recent years.
Maintained above 500%, the upward momentum is swift and violent
.
25 billion)
.
The original research drug was approved to enter the domestic market in 2017 for the treatment of systemic sclerosis-related interstitial lung disease and for the treatment of idiopathic pulmonary fibrosis
.
According to data from Mi Nei.
com, in the first half of 2021 , the sales of this product in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have exceeded 20 million yuan, with an average increase in recent years.
Maintained above 500%, the upward momentum is swift and violent
.
Figure 3: The situation of the enterprises that reported the production of nintedanib ethanesulfonate soft capsules earlier
Source: One-click search on Mi Nei.
com
com
CSPC Enbipu Pharmaceutical Co.
, Ltd.
was the first to submit an application for the 4 types of generic listing of nintedanib ethanesulfonate soft capsules in 2019, and won the first domestic imitation in March this year.
At present, in addition to Kelun, Jiangsu Hao Sen Pharmaceutical also submitted a listing application in September this year
.
, Ltd.
was the first to submit an application for the 4 types of generic listing of nintedanib ethanesulfonate soft capsules in 2019, and won the first domestic imitation in March this year.
At present, in addition to Kelun, Jiangsu Hao Sen Pharmaceutical also submitted a listing application in September this year
.
For systemic antibacterial drug Cefmetazole Sodium/Sodium Chloride Injection, currently only one company has obtained approval.
Suzhou Otsuka Pharmaceutical applied for production according to category 3 imitations in 2018 and was approved at the end of 2020.
At present, Beijing Rui The relevant acceptance number of Yee Pharmaceutical is under review and approval, and Kelun is still expected to hit the second domestic company and further expand its infusion product line
.
Suzhou Otsuka Pharmaceutical applied for production according to category 3 imitations in 2018 and was approved at the end of 2020.
At present, Beijing Rui The relevant acceptance number of Yee Pharmaceutical is under review and approval, and Kelun is still expected to hit the second domestic company and further expand its infusion product line
.
2021 is coming to an end.
As of now, Kelun has reported the production of 1 new biological class 1 drug Tetlizumab injection and 28 generic drugs this year (all are declared according to the new classification, and they are deemed to have been reviewed after approval) , Including omega-3 fish oil medium and long-chain fat emulsion/amino acid (16)/glucose (36%) injection, etropopaethanolamine tablets, posaconazole oral suspension, escitalopram oxalate oral solution, Vonola fumarate green tablets, gadobutrol injection, tofacitib citrate sustained-release tablets, titagliptin hydrobromide tablets, sacubitril and valsartan sodium tablets and brimonidine Morolol eye drops are expected to impact the first imitation
.
As of now, Kelun has reported the production of 1 new biological class 1 drug Tetlizumab injection and 28 generic drugs this year (all are declared according to the new classification, and they are deemed to have been reviewed after approval) , Including omega-3 fish oil medium and long-chain fat emulsion/amino acid (16)/glucose (36%) injection, etropopaethanolamine tablets, posaconazole oral suspension, escitalopram oxalate oral solution, Vonola fumarate green tablets, gadobutrol injection, tofacitib citrate sustained-release tablets, titagliptin hydrobromide tablets, sacubitril and valsartan sodium tablets and brimonidine Morolol eye drops are expected to impact the first imitation
.
Source: CDE official website, Minet database
The review data statistics are as of December 20, if there are any errors or omissions, please correct me
.
.
On December 17, Sichuan Kelun submitted an application for the 4 types of imitations of nintedanib ethanesulfonate soft capsules.
The first domestic imitation of this product was taken by CSPC in March this year; on December 20, Hunan Kelun Submitted the application for the imitation of Cefmetazole Sodium/Sodium Chloride Injection for 3 types of listing.
At present, only Suzhou Otsuka Pharmaceutical has obtained approval for this product.
.
.
The latest two products of Kelun are expected to win the domestic market.
Second
.
The first domestic imitation of this product was taken by CSPC in March this year; on December 20, Hunan Kelun Submitted the application for the imitation of Cefmetazole Sodium/Sodium Chloride Injection for 3 types of listing.
At present, only Suzhou Otsuka Pharmaceutical has obtained approval for this product.
.
.
The latest two products of Kelun are expected to win the domestic market.
Second
.
Figure 1: The situation of Kelun's recently reported products
Source: CDE official website
Figure 2: Sales of nintedanib (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
It is reported that nintedanib is a small molecule tyrosine kinase inhibitor, the original research company is Boehringer Ingelheim, and its global sales in 2020 will exceed 2 billion euros (approximately US$2.
25 billion)
.
The original research drug was approved to enter the domestic market in 2017 for the treatment of systemic sclerosis-related interstitial lung disease and for the treatment of idiopathic pulmonary fibrosis
.
According to data from Mi Nei.
com, in the first half of 2021 , the sales of this product in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have exceeded 20 million yuan, with an average increase in recent years.
Maintained above 500%, the upward momentum is swift and violent
.
25 billion)
.
The original research drug was approved to enter the domestic market in 2017 for the treatment of systemic sclerosis-related interstitial lung disease and for the treatment of idiopathic pulmonary fibrosis
.
According to data from Mi Nei.
com, in the first half of 2021 , the sales of this product in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have exceeded 20 million yuan, with an average increase in recent years.
Maintained above 500%, the upward momentum is swift and violent
.
Figure 3: The situation of the enterprises that reported the production of nintedanib ethanesulfonate soft capsules earlier
Source: One-click search on Mi Nei.
com
com
CSPC Enbipu Pharmaceutical Co.
, Ltd.
was the first to submit an application for the 4 types of generic listing of nintedanib ethanesulfonate soft capsules in 2019, and won the first domestic imitation in March this year.
At present, in addition to Kelun, Jiangsu Hao Sen Pharmaceutical also submitted a listing application in September this year
.
, Ltd.
was the first to submit an application for the 4 types of generic listing of nintedanib ethanesulfonate soft capsules in 2019, and won the first domestic imitation in March this year.
At present, in addition to Kelun, Jiangsu Hao Sen Pharmaceutical also submitted a listing application in September this year
.
For systemic antibacterial drug Cefmetazole Sodium/Sodium Chloride Injection, currently only one company has obtained approval.
Suzhou Otsuka Pharmaceutical applied for production according to category 3 imitations in 2018 and was approved at the end of 2020.
At present, Beijing Rui The relevant acceptance number of Yee Pharmaceutical is under review and approval, and Kelun is still expected to hit the second domestic company and further expand its infusion product line
.
Suzhou Otsuka Pharmaceutical applied for production according to category 3 imitations in 2018 and was approved at the end of 2020.
At present, Beijing Rui The relevant acceptance number of Yee Pharmaceutical is under review and approval, and Kelun is still expected to hit the second domestic company and further expand its infusion product line
.
2021 is coming to an end.
As of now, Kelun has reported the production of 1 new biological class 1 drug Tetlizumab injection and 28 generic drugs this year (all are declared according to the new classification, and they are deemed to have been reviewed after approval) , Including omega-3 fish oil medium and long-chain fat emulsion/amino acid (16)/glucose (36%) injection, etropopaethanolamine tablets, posaconazole oral suspension, escitalopram oxalate oral solution, Vonola fumarate green tablets, gadobutrol injection, tofacitib citrate sustained-release tablets, titagliptin hydrobromide tablets, sacubitril and valsartan sodium tablets and brimonidine Morolol eye drops are expected to impact the first imitation
.
As of now, Kelun has reported the production of 1 new biological class 1 drug Tetlizumab injection and 28 generic drugs this year (all are declared according to the new classification, and they are deemed to have been reviewed after approval) , Including omega-3 fish oil medium and long-chain fat emulsion/amino acid (16)/glucose (36%) injection, etropopaethanolamine tablets, posaconazole oral suspension, escitalopram oxalate oral solution, Vonola fumarate green tablets, gadobutrol injection, tofacitib citrate sustained-release tablets, titagliptin hydrobromide tablets, sacubitril and valsartan sodium tablets and brimonidine Morolol eye drops are expected to impact the first imitation
.
Source: CDE official website, Minet database
The review data statistics are as of December 20, if there are any errors or omissions, please correct me
.
.
On December 17, Sichuan Kelun submitted an application for the 4 types of imitations of nintedanib ethanesulfonate soft capsules.
The first domestic imitation of this product was taken by CSPC in March this year; on December 20, Hunan Kelun Submitted the application for the imitation of Cefmetazole Sodium/Sodium Chloride Injection for 3 types of listing.
At present, only Suzhou Otsuka Pharmaceutical has obtained approval for this product.
.
.
The latest two products of Kelun are expected to win the domestic market.
Second
.
The first domestic imitation of this product was taken by CSPC in March this year; on December 20, Hunan Kelun Submitted the application for the imitation of Cefmetazole Sodium/Sodium Chloride Injection for 3 types of listing.
At present, only Suzhou Otsuka Pharmaceutical has obtained approval for this product.
.
.
The latest two products of Kelun are expected to win the domestic market.
Second
.
Figure 1: The situation of Kelun's recently reported products
Source: CDE official website
Figure 2: Sales of nintedanib (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
It is reported that nintedanib is a small molecule tyrosine kinase inhibitor, the original research company is Boehringer Ingelheim, and its global sales in 2020 will exceed 2 billion euros (approximately US$2.
25 billion)
.
The original research drug was approved to enter the domestic market in 2017 for the treatment of systemic sclerosis-related interstitial lung disease and for the treatment of idiopathic pulmonary fibrosis
.
According to data from Mi Nei.
com, in the first half of 2021 , the sales of this product in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have exceeded 20 million yuan, with an average increase in recent years.
Maintained above 500%, the upward momentum is swift and violent
.
Enterprise Enterprise Enterprise Disease Disease Disease Hospital Hospital Hospital25 billion)
.
The original research drug was approved to enter the domestic market in 2017 for the treatment of systemic sclerosis-related interstitial lung disease and for the treatment of idiopathic pulmonary fibrosis
.
According to data from Mi Nei.
com, in the first half of 2021 , the sales of this product in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have exceeded 20 million yuan, with an average increase in recent years.
Maintained above 500%, the upward momentum is swift and violent
.
Figure 3: The situation of the enterprises that reported the production of nintedanib ethanesulfonate soft capsules earlier
Source: One-click search on Mi Nei.
com
com
CSPC Enbipu Pharmaceutical Co.
, Ltd.
was the first to submit an application for the 4 types of generic listing of nintedanib ethanesulfonate soft capsules in 2019, and won the first domestic imitation in March this year.
At present, in addition to Kelun, Jiangsu Hao Sen Pharmaceutical also submitted a listing application in September this year
.
, Ltd.
was the first to submit an application for the 4 types of generic listing of nintedanib ethanesulfonate soft capsules in 2019, and won the first domestic imitation in March this year.
At present, in addition to Kelun, Jiangsu Hao Sen Pharmaceutical also submitted a listing application in September this year
.
For systemic antibacterial drug Cefmetazole Sodium/Sodium Chloride Injection, currently only one company has obtained approval.
Suzhou Otsuka Pharmaceutical applied for production according to category 3 imitations in 2018 and was approved at the end of 2020.
At present, Beijing Rui The relevant acceptance number of Yee Pharmaceutical is under review and approval, and Kelun is still expected to hit the second domestic company and further expand its infusion product line
.
Suzhou Otsuka Pharmaceutical applied for production according to category 3 imitations in 2018 and was approved at the end of 2020.
At present, Beijing Rui The relevant acceptance number of Yee Pharmaceutical is under review and approval, and Kelun is still expected to hit the second domestic company and further expand its infusion product line
.
2021 is coming to an end.
As of now, Kelun has reported the production of 1 new biological class 1 drug Tetlizumab injection and 28 generic drugs this year (all are declared according to the new classification, and they are deemed to have been reviewed after approval) , Including omega-3 fish oil medium and long-chain fat emulsion/amino acid (16)/glucose (36%) injection, etropopaethanolamine tablets, posaconazole oral suspension, escitalopram oxalate oral solution, Vonola fumarate green tablets, gadobutrol injection, tofacitib citrate sustained-release tablets, titagliptin hydrobromide tablets, sacubitril and valsartan sodium tablets and brimonidine Morolol eye drops are expected to impact the first imitation
.
As of now, Kelun has reported the production of 1 new biological class 1 drug Tetlizumab injection and 28 generic drugs this year (all are declared according to the new classification, and they are deemed to have been reviewed after approval) , Including omega-3 fish oil medium and long-chain fat emulsion/amino acid (16)/glucose (36%) injection, etropopaethanolamine tablets, posaconazole oral suspension, escitalopram oxalate oral solution, Vonola fumarate green tablets, gadobutrol injection, tofacitib citrate sustained-release tablets, titagliptin hydrobromide tablets, sacubitril and valsartan sodium tablets and brimonidine Morolol eye drops are expected to impact the first imitation
.
Source: CDE official website, Minet database
Source: CDE official website, Minet database The review data statistics are as of December 20, if there are any errors or omissions, please correct me
.
.
